Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 4Unknown 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 267Oxaliplatin 194Carboplatin 189Capecitabine 183Docetaxel 176apatinib 164Paclitaxel 158Bevacizumab 155Gemcitabine 154Radiotherapy 146camrelizumab 145Fluorouracil 144Cyclophosphamide 123Irinotecan 119Drug Therapy 118sintilimab 107Etoposide 99anlotinib 90S 1 (combination) 88Leucovorin 85pembrolizumab 82Pemetrexed 78Doxorubicin 77toripalimab 76tislelizumab 75Dexamethasone 70Trastuzumab 65Neoadjuvant Therapy 64Rituximab 62Cetuximab 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × tepotinib × Clear all
NCT04591431 2023-10-03

ROME

Fondazione per la Medicina Personalizzata

Phase 2 Unknown
400 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04647838 2020-12-02

Tepotinib in Solid Tumors Harboring MET Alterations

Chungbuk National University Hospital

Phase 2 Unknown
100 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡